Pathological Gambling
2
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Angeles TherapeuticsCA - Los Angeles
1 programImpulsivity in Pathological GamblingN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Emalex BiosciencesEcopipam
Angeles TherapeuticsImpulsivity in Pathological Gambling
AbbottfMRI
Clinical Trials (3)
Total enrollment: 211 patients across 3 trials
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
Start: Oct 2010Est. completion: Aug 201234 patients
Phase 2Completed
Impulsivity in Pathological Gambling
Start: Mar 2007Est. completion: Aug 2009120 patients
N/ACompleted
Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)
Start: Nov 2004Est. completion: Dec 201057 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.